Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 20/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9926746 | 1.00 | FAAH (0.79) | FAAH | |
| SCHEMBL9899138 | 0.89 | FAAH (0.68) | FAAH | |
| SCHEMBL9899356 | 0.89 | FAAH (0.65) | FAAH | |
| SCHEMBL3405219 | 0.88 | FAAH (1.00) | FAAH | |
| SCHEMBL9899372 | 0.88 | FAAH (0.64) | FAAH | |
| SCHEMBL9925726 | 0.87 | FAAH (0.60) | FAAH | |
| SCHEMBL9899296 | 0.87 | FAAH (0.78) | FAAH | |
| SCHEMBL9899425 | 0.87 | FAAH (0.78) | FAAH | |
| SCHEMBL9898193 | 0.86 | FAAH (0.62) | FAAH | |
| SCHEMBL9898872 | 0.86 | FAAH (0.71) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149711-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED | 2012-06-14 | — | — | US | claimed |
| US-20120149696-A1 | ETHYLENE DIAMINE MODULATORS OF FATTY ACID HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-14 | — | — | US | claimed |
| US-20120149711-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149711-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, OXTR | FAAH 137/4885 |
| US-20120149696-A1 | ETHYLENE DIAMINE MODULATORS OF FATTY ACID HYDROLASE | FAAH, FAAH2, APEH | FAAH 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.